Lv3
394 积分 2025-06-06 加入
The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity
6小时前
待确认
The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer
1天前
已完结
Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
1天前
已完结
Gastric cancer
1天前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
5天前
已完结
The next generation of antibody–drug conjugates
5天前
已完结
PLD1-driven oncogenic secretion creates a therapeutic vulnerability in chromosome 3q-amplified NSCLC
5天前
已完结
Opportunities and challenges of targeting cGAS–STING in cancer
5天前
已完结
Targeting STING to generate therapeutic anti-tumor immunity
5天前
已完结
皖公网安备34019202002308
